Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model

Neurobiology of Aging

Volumn 34, Issue 6, 2013, Pages 1555-1563

  Peng, Cai Xia ^a,b   Hu, Juan ^a,b   Liu, Dan ^a   Hong, Xiao Ping ^a   Wu, Yuan Yuan ^a   Zhu, Ling Qiang ^a   Wang, Jian Zhi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Alzheimer's disease; Disease modifying intervention; Glycogen synthase kinase 3 ; Melatonin

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; GAMMA SECRETASE; GLYCOGEN SYNTHASE KINASE 3BETA; MELATONIN; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SURVIVAL RATE; TRANSGENIC MOUSE; TREATMENT DURATION;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MELATONIN; MEMORY DISORDERS; MICE; PROTEIN KINASE INHIBITORS;

EID: 84875270977     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.12.010     Document Type: Article

References (47)

1. Bennecib M., Gong C.X., Grundke-Iqbal I., Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000, 485:87-93.
2. Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G., Brunden K.R. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging 1999, 20:581-589.
3. Bondy S.C., Yang Y.E., Walsh T.J., Gie Y.W., Lahiri D.K. Dietary modulation of age-related changes in cerebral pro-oxidant status. Neurochem. Int. 2002, 40:123-130.
4. Chauhan N.B., Siegel G.J., Feinstein D.L. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology 2005, 48:93-104.
5. Feng Z., Chang Y., Cheng Y., Zhang B.L., Qu Z.W., Qin C., Zhang J.T. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal Res. 2004, 37:129-136.
6. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y.C., Zaidi M.S., Wisniewski H.M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261:6084-6089.
7. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A 1986, 83:4913-4917.
8. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005, 27:119-130.
9. Hardeland R., Cardinali D.P., Srinivasan V., Spence D.W., Brown G.M., Pandi-Perumal S.R. Melatonin-a pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93:350-384.
10. Hongpaisan J., Sun M.K., Alkon D.L. PKC epsilon activation prevents synaptic loss, Abeta elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J. Neurosci. 2011, 31:630-643.
11. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104:1433-1439.
12. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
13. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., Ladecola C., Brent Clark H., Carlsonll G. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
14. Hu J., Wang X., Liu D., Wang Q., Zhu L.Q. Olfactory deficits induce neurofilament hyperphosphorylation. Neurosci. Lett. 2012, 506:180-183.
15. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997, 56:965-973.
16. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 2006, 103:5161-5166.
17. Jiang X., Tian Q., Wang Y., Zhou X.W., Xie J.Z., Wang J.Z., Zhu L.Q. Acetyl-L-carnitine ameliorates spatial memory deficits induced by inhibition of phosphoinositol-3 kinase and protein kinase C. J. Neurochem. 2011, 118:864-878.
18. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
19. LaFerla F.M., Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med. 2005, 11:170-176.
20. Lahiri D.K. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J. Pineal Res. 1999, 26:137-146.
21. Lahiri D.K., Chen D., Ge Y.W., Bondy S.C., Sharman E.H. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J. Pineal Res. 2004, 36:224-231.
22. Lahiri D.K., Ge Y.W., Sharman E.H., Bondy S.C. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J. Pineal Res. 2004, 36:217-223.
23. Lee M.S., Kao S.C., Lemere C.A., Xia W., Tseng H.C., Zhou Y., Neve R., Ahlijanian M.K., Tsai L.H. APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 2003, 163:83-95.
24. Levy M.L., Cummings J.L., Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 1999, 45(Suppl. 1):15-22.
25. Liao K., Liu D., Zhu L.Q. Enriched odor exposure decrease tau phosphorylation in the rat hippocampus and cortex. Neurosci. Lett. 2012, 507:22-26.
26. Liu R.Y., Zhou J.N., van Heerikhuize J., Hofman M.A., Swaab D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J. Clin. Endocrinol. Metab. 1999, 84:323-327.
27. Liu S.J., Zhang A.H., Li H.L., Wang Q., Deng H.M., Netzer W.J., Xu H., Wang J.Z. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem. 2003, 87:1333-1344.
28. Luchetti F., Canonico B., Betti M., Arcangeletti M., Pilolli F., Piroddi M., Canesi L., Papa S., Galli F. Melatonin signaling and cell protection function. FASEB J. 2010, 24:3603-3624.
29. Mahlberg R., Walther S., Eichmann U., Tracik F., Kunz D. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. Arch. Gerontol. Geriatr. 2007, 45:19-26.
30. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 2003, 85:1101-1108.
31. Maurizi C.P. Choroid plexus portals and a deficiency of melatonin can explain the neuropathology of Alzheimer's disease. Med. Hypotheses 2010, 74:1059-1066.
32. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 2011, 34:185-204.
33. Ohashi Y., Okamoto N., Uchida K., Iyo M., Mori N., Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol. Psychiatry 1999, 45:1646-1652.
34. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
35. Pierrot N., Santos S.F., Feyt C., Morel M., Brion J.P., Octave J.N. Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. J. Biol. Chem. 2006, 281:39907-39914.
36. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 1998, 56:359-384.
37. Sharman E.H., Sharman K.G., Ge Y.W., Lahiri D.K., Bondy S.C. Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin. J. Pineal Res. 2004, 36:165-170.
38. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimers Dis. 2006, 9(3 Suppl.):309-317.
39. Wang J.Z., Grundke-Iqbal I., Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 2007, 25:59-68.
40. Wang J.Z., Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog. Neurobiol. 2008, 85:148-175.
41. Yamamoto T., Hirano A. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol. Appl. Neurobiol. 1986, 12:3-9.
42. Yin Y.Y., Liu H., Cong X.B., Liu Z., Wang Q., Wang J.Z., Zhu L.Q. Acetyl-L-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats. J. Alzheimers Dis. 2010, 19:735-746.
43. Zhou P., Chen Z., Zhao N., Liu D., Guo Z.Y., Tan L., Hu J., Wang Q., Wang J.Z., Zhu L.Q. Acetyl-L-carnitine attenuates homocysteine-induced Alzheimer-like histopathological and behavioral abnormalities. Rejuvenation Res. 2011, 14:669-679.
44. Zhu L.Q., Liu D., Hu J., Cheng J., Wang S.H., Wang Q., Wang F., Chen J.G., Wang J.Z. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J. Neurosci. 2010, 30:3624-3633.
45. Zhu L.Q., Wang S.H., Ling Z.Q., Wang D.L., Wang J.Z. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J. Pineal Res. 2004, 37:71-77.
46. Zhu L.Q., Wang S.H., Liu D., Yin Y.Y., Tian Q., Wang X.C., Wang Q., Chen J.G., Wang J.Z. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J. Neurosci. 2007, 27:12211-12220.
47. Zhu L.Q., Zheng H.Y., Peng C.X., Liu D., Li H.L., Wang Q., Wang J.Z. Protein phosphatase 2A facilitates axonogenesis by dephosphorylating CRMP2. J. Neurosci. 2010, 30:3839-3848.